CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2

CytomX Therapeutics (CTMX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.18 per share when it actually produced earnings of $0.27, delivering a surprise of +50%.Over the last four quarter ...